Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artículo científico |
| Lenguaje: | en |
| Publicado: |
Inflammopharmacology
2026
|
| Materias: | |
| Acceso en línea: | https://pubmed.ncbi.nlm.nih.gov/41986787/ |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1868266061961363457 |
|---|---|
| author | Vishnuram, Ganapathy Purushothaman, Ramamoorthy Ramanathan, Thirugnanasambandam |
| author_facet | Vishnuram, Ganapathy Purushothaman, Ramamoorthy Ramanathan, Thirugnanasambandam Vishnuram, Ganapathy Purushothaman, Ramamoorthy Ramanathan, Thirugnanasambandam |
| collection | PubMed - marine biology |
| contents | Stigmasterol ameliorates Freund's complete adjuvant-induced polyarthritis in rats. Vishnuram, Ganapathy Purushothaman, Ramamoorthy Ramanathan, Thirugnanasambandam Animals Freund's Adjuvant Arthritis, Experimental Rats, Wistar Rats Stigmasterol Male Methotrexate Dose-Response Relationship, Drug Antirheumatic Agents Edema To evaluate the anti-arthritic and disease-modifying potential of stigmasterol (STG), a plant-derived bioactive compound, in Freund's Complete Adjuvant (FCA)-induced polyarthritis in rats. Experimental arthritis was induced in albino Wistar rats using FCA. The anti-arthritic efficacy of STG was assessed through primary and secondary paw edema, arthritis index, and body-weight changes. Biochemical, haematological, and immunological parameters were evaluated, along with mRNA expression of key mediators using RT-PCR. Histopathological analysis of bone, kidney, and spleen tissues, as well as macroscopic and radiographic joint assessments, was performed. STG was administered orally at doses of 150 and 300 mg/kg and compared with methotrexate (MTX). FCA induction produced severe arthritic manifestations, including marked paw swelling, an elevated arthritis index, increased rheumatoid factor and anti-cyclic citrullinated peptide levels, and upregulation of inflammatory mediators (TNF-α, NF-κB, IL-1β, IRAK, and IL-17), along with radiographic joint damage and histopathological abnormalities. STG treatment significantly reduced paw edema, improved arthritis severity, and normalized biochemical and haematological parameters in a dose-dependent manner. The higher dose (300 mg/kg) showed efficacy comparable to MTX and significantly enhanced IL-10 expression, indicating restoration of immune balance. Stigmasterol exhibits potent anti-arthritic, disease-modifying, and organ-protective effects in FCA-induced arthritis, highlighting its therapeutic potential in arthritis management. |
| format | Artículo científico |
| id | pubmed_41986787 |
| institution | PubMed |
| language | en |
| publishDate | 2026 |
| publisher | Inflammopharmacology |
| record_format | pubmed |
| spellingShingle | Stigmasterol ameliorates Freund's complete adjuvant-induced polyarthritis in rats. Vishnuram, Ganapathy Purushothaman, Ramamoorthy Ramanathan, Thirugnanasambandam Animals Freund's Adjuvant Arthritis, Experimental Rats, Wistar Rats Stigmasterol Male Methotrexate Dose-Response Relationship, Drug Antirheumatic Agents Edema Stigmasterol ameliorates Freund's complete adjuvant-induced polyarthritis in rats. Vishnuram, Ganapathy Purushothaman, Ramamoorthy Ramanathan, Thirugnanasambandam Animals Freund's Adjuvant Arthritis, Experimental Rats, Wistar Rats Stigmasterol Male Methotrexate Dose-Response Relationship, Drug Antirheumatic Agents Edema To evaluate the anti-arthritic and disease-modifying potential of stigmasterol (STG), a plant-derived bioactive compound, in Freund's Complete Adjuvant (FCA)-induced polyarthritis in rats. Experimental arthritis was induced in albino Wistar rats using FCA. The anti-arthritic efficacy of STG was assessed through primary and secondary paw edema, arthritis index, and body-weight changes. Biochemical, haematological, and immunological parameters were evaluated, along with mRNA expression of key mediators using RT-PCR. Histopathological analysis of bone, kidney, and spleen tissues, as well as macroscopic and radiographic joint assessments, was performed. STG was administered orally at doses of 150 and 300 mg/kg and compared with methotrexate (MTX). FCA induction produced severe arthritic manifestations, including marked paw swelling, an elevated arthritis index, increased rheumatoid factor and anti-cyclic citrullinated peptide levels, and upregulation of inflammatory mediators (TNF-α, NF-κB, IL-1β, IRAK, and IL-17), along with radiographic joint damage and histopathological abnormalities. STG treatment significantly reduced paw edema, improved arthritis severity, and normalized biochemical and haematological parameters in a dose-dependent manner. The higher dose (300 mg/kg) showed efficacy comparable to MTX and significantly enhanced IL-10 expression, indicating restoration of immune balance. Stigmasterol exhibits potent anti-arthritic, disease-modifying, and organ-protective effects in FCA-induced arthritis, highlighting its therapeutic potential in arthritis management. |
| title | Stigmasterol ameliorates Freund's complete adjuvant-induced polyarthritis in rats. |
| topic | Animals Freund's Adjuvant Arthritis, Experimental Rats, Wistar Rats Stigmasterol Male Methotrexate Dose-Response Relationship, Drug Antirheumatic Agents Edema |
| url | https://pubmed.ncbi.nlm.nih.gov/41986787/ |